Pipeline

  • PROGRAM
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2

P-TEFb Program

ENITOCICLIB

ENITOCICLIB* CDK9 inhibitor
Best-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
MYC-rearranged , Diffuse Large B-cell Lymphoma (DLBCL), Non-GCB DLBCL, Peripheral T-cell Lymphoma (in partnership with NIH)

VersAptx™ Platform

VIP236

αvβ3 - optCPT SMDC
First-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Multiple Solid Tumors

VIP943

Anti-CD123 - KSPi ADC
Best-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Leukemias & Myelodysplastic Syndrome (MDS)

VIP924

Anti-CXCR5 - KSPi ADC
First-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
B-cell Malignancies

Anti-CD33 - KSPi ADC
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Leukemias & MDS

Undisclosed Target 1 - KSPi ADC
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Solid Tumors

Undisclosed Target 2 - KSPi ADC
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Solid Tumors

*Also known as VIP152.
ADC, antibody-drug conjugate; CDK, cyclin-dependent kinase;  GCB, germinal center B-cell;  intravenous; KSPi, kinesin spindle protein inhibitor;  optCPT, optimized camptothecin; P-TEFb, positive transcription elongation factor B; SMDC, small molecule drug conjugate.

Next-Generation Adc Technology

Bioconjugation Platform

Antibody-drug conjugates (ADCs) are an established therapeutic approach in oncology used to selectively deliver potent cytotoxins directly to tumor cells, with the goal of maximizing toxicity in tumor cells, while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells. 

 

Learn more